MX2023005447A - Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos. - Google Patents

Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.

Info

Publication number
MX2023005447A
MX2023005447A MX2023005447A MX2023005447A MX2023005447A MX 2023005447 A MX2023005447 A MX 2023005447A MX 2023005447 A MX2023005447 A MX 2023005447A MX 2023005447 A MX2023005447 A MX 2023005447A MX 2023005447 A MX2023005447 A MX 2023005447A
Authority
MX
Mexico
Prior art keywords
crystalline solid
methods
meglumine salt
bcl
making
Prior art date
Application number
MX2023005447A
Other languages
English (en)
Inventor
Nathan Guz
Liang Liao
Yuxi Ning
Jane Li
Yue Lu
Albert Shi
Original Assignee
Unity Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unity Biotechnology Inc filed Critical Unity Biotechnology Inc
Publication of MX2023005447A publication Critical patent/MX2023005447A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Se proporcionan sales sólidas cristalinas de meglumina de ácido (R)-5-(4-clorofenil)-1-isopropil-2- metil-4-(3-(4-(4-((4-((1-fenil tio)-4-(4-((fosfonooxi)metil) piperidin-1-il) butan-2-il) amino)-3- (trifluorometil)sulfonil) fenil)sulfonamido)fenil)pipera zin-1-il)fenil)-1H-pirrol-3 carboxílico. También se describen composiciones farmacéuticas que contienen uno o más de los compuestos de sal sólida cristalina de meglumina y métodos para administrar los compuestos de sal sólida cristalina de meglumina a un sujeto. También se proporcionan métodos para la preparación de los compuestos de sal sólida cristalina de meglumina.
MX2023005447A 2020-11-10 2020-11-10 Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos. MX2023005447A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/127666 WO2022099431A1 (en) 2020-11-10 2020-11-10 Crystalline solid meglumine salt inhibitor of bcl and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2023005447A true MX2023005447A (es) 2023-09-25

Family

ID=81600684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005447A MX2023005447A (es) 2020-11-10 2020-11-10 Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.

Country Status (10)

Country Link
US (1) US20240043456A1 (es)
EP (1) EP4244231A1 (es)
JP (1) JP2023547959A (es)
KR (1) KR20230145313A (es)
CN (1) CN117062808A (es)
AU (1) AU2020477113A1 (es)
CA (1) CA3199345A1 (es)
MX (1) MX2023005447A (es)
TW (1) TW202235081A (es)
WO (1) WO2022099431A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951115B2 (en) 2021-04-13 2024-04-09 Unity Biotechnology, Inc. Methods of treating retinal vasculopathies
IL312330A (en) 2021-10-25 2024-06-01 Kymera Therapeutics Inc TYK2 joints and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897055C (en) * 2013-01-16 2021-04-20 The Regents Of The University Of Michigan Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same
WO2019033122A1 (en) * 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
US20200354336A9 (en) * 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells

Also Published As

Publication number Publication date
EP4244231A1 (en) 2023-09-20
TW202235081A (zh) 2022-09-16
JP2023547959A (ja) 2023-11-14
CN117062808A (zh) 2023-11-14
US20240043456A1 (en) 2024-02-08
CA3199345A1 (en) 2022-05-19
KR20230145313A (ko) 2023-10-17
AU2020477113A1 (en) 2023-06-22
WO2022099431A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
RU2498983C2 (ru) Соединения фениламинопиримидина и их применения
MX2023005447A (es) Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos.
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2368604C2 (ru) Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2392275C2 (ru) Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
RU2011138970A (ru) Активаторы растворимой гуанилатциклазы
RU2011134634A (ru) Индуцирующие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
JP2008517926A5 (es)
RU2011105257A (ru) Модулирующие апоптоз композиции с контролируемым высвобождением и способы лечения заболеваний уха
JP2013510876A5 (es)
RU2005132616A (ru) Производные 2-фенокси и 2-фенилсульфонамида с ссr3 антагонистической активностью для лечения астмы и других воспалительных или иммунологических заболеваний
RU2000128036A (ru) Амидиновые соединения
JP2017535525A5 (es)
CA2585053A1 (en) Substituted n-acyl (hetero)aryl compounds as c-fms kinase inhibitors
JP2013513605A5 (es)
RU2011140869A (ru) Пиперазиновое соединение, ингибирующее простагландин-d-синтазу
RU2010134361A (ru) Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа
RU2008129641A (ru) Ингибиторы ccr9 активности
CL2020002371A1 (es) Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida
JP2021501179A5 (es)
NO168476C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-(4-(4-(4-(((2,4-difluorfenyl)-2-(1h-azolylmetyl)-1,3-dioxolan-4-yl)metoksy)fenyl)-1-piperazinyl)fenyl)triazoloner.
RU2008149927A (ru) Производные 1-[(4-[ензоил(метил)амино]-3-(фенил)бутил]азетидина для лечения желудочно-кишечных расстройств
ATE473212T1 (de) Hiv-inhibierende 2-(4-cyanophenyl)-6- hydroxylaminopyrimidine
JP2009531363A5 (es)